AbbVie Filed Patent Suits To Delay Competition, Court Told

By Jeannie O'Sullivan (February 7, 2018, 6:40 PM EST) -- The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were "anti-competitive weapons" used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade Commission said Wednesday while opening the bench trial in the agency's antitrust suit in Pennsylvania federal court....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!